Navigation Links
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Date:11/1/2008

ocytopenic purpura, psoriasis, lupus, rheumatoid arthritis and interstitial nephritis), pulmonary disorders (dyspnea, pneumonia, bronchiolitis obliterans, interstitial pneumonitis and sarcoidosis), colitis (ulcerative and hemorrhagic/ischemic colitis), pancreatitis, and ophthalmologic disorders (decrease or loss of vision, retinopathy including macular edema and retinal thrombosis/hemorrhages, optic neuritis and papilledema). Adverse reactions reported during post-approval use of PEGASYS therapy, with and without ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal).

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. For additional information about the U.S. pharmaceuticals business, visit our website http://www.rocheusa.com. Product and treatment information for U.S. healthcare professionals is available at http://www.RocheExchange.com.

All trademarks used or mentioned in this release are protected by law.

PegIntronTM is a trademark product of Schering Plough Corporation.

(1) Rumi M, Aghemo A, Prati G, et al. Randomized study comparing peginterferon-alfa-2a plus ribavirin and peginterferon-alfa-2b plus ribavirin in naive patients with chronic hepatitis C: final results of the Milan Safety Tolerability Study. Abstract presented at the American Association for the Study of Liver Disease; 31 October 2008; San Fr
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
2. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
5. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
6. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
... ATLANTA--(BUSINESS WIRE)--May 22, 2007 - MIV Therapeutics,(OTCBB:MIVT) ... coatings and advanced drug delivery systems for,Cardiovascular ... to announce that results from an animal ... stent to J&J's Cypher Stent will be ...
... 23, 2007 - Neurogen,Corporation (Nasdaq: NRGN) today announced ... clinical studies for NG2-73, the Company's,lead compound for ... American Psychiatric Association (APA) annual meeting in San,Diego. ... chronic,insomnia patients are currently being conducted by the ...
Other Medicine Technology:MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 2MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 3MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007 4Neurogen Proprietary Insomnia Compound Data Presented at American,Psychiatric Association Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at American,Psychiatric Association Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at American,Psychiatric Association Annual Meeting 4Neurogen Proprietary Insomnia Compound Data Presented at American,Psychiatric Association Annual Meeting 5
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... science and inspired by passion, CONNEXION Healthcare (CXHC) ... communications companies dedicated to developing high-quality, scientific programs ... all therapeutic areas to improve patient care. CXHC ... quality execution, business integrity, and results are the ...
... Breakfast is the most important ... the metabolism and is the first ... this report from Kellogg at: ... audio, text, graphics and photos for ...
... announces participation of Dr. Larry Kaskel, Founder and Medical Director of ... Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes." , ... ... , the first of its kind online medical conference for primary ...
... SCHENECTADY, N.Y., Feb. 18 The National Committee ... HMO/POS plan, MVP Health Plan Inc., Excellent Accreditation ... for service and clinical quality that meets or ... organization,s rigorous requirements for consumer protection and quality ...
... Continuing its efforts to educate, inform, and empower ... patient-focused organization, is hosting its 25-minute live call-in show, ... February 23, 2009 at 6:00 PM on Channel 21. ... Chiropractor and Founder of the Balancing Center in Chicago ...
... Mutual releases research revealing stark differences in cost ... nursing homes across the U.S.MILWAUKEE, Feb. 18 ... for certain long-term care services than others, according ... Northwestern Mutual .The survey of nearly ...
Other Medicine News:Health News:CONNEXION Healthcare Announces New Hires for 2009 2Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 2Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 3Health News:National Committee For Quality Assurance (NCQA) Awards MVP Health Care Excellent Accreditation Status For Its HMO/POS Plan 2Health News:Save Your Money and Your Health 2Health News:Location, Location, Location: Cost of Long-Term Care Services Vary Widely by Region 2Health News:Location, Location, Location: Cost of Long-Term Care Services Vary Widely by Region 3
... has developed a new, integrated technology ... heartbeat-by-heartbeat, ECG monitoring, analysis and response, ... service is initially focused on helping ... arrhythmia. Time is of the essence ...
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
Minimal M9CA Broth...
An agent used for making solid microbiological media....
Medicine Products: